Category: CAR T-Cell therapy

Home / CAR T-Cell therapy

Categories

PiggyBac Transposon System: A Revolutionary Tool in Cancer Gene Therapy

Introduction: What is the PiggyBac Transposon System? The PiggyBac transposon system is a non-viral gene delivery tool that enables the insertion of specific genes into host genomes. Originally discov...

Breakthrough Treatments for Advanced Breast Cancer in 2025

Latest breakthroughs in the treatment of breast cancerBy 2025, the domain of advanced breast cancer treatment is swiftly transforming, providing renewed optimism to patients globally. Recent advanceme...

Satri-cel CAR T-Cell Therapy: A New Era in Gastric Cancer Treatment

CAR T Cell therapy for gastric cancer The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting introduced an important new cancer treatment: Satricabtagene autoleucel (satri-cel), a CAR T...

Advanced Innovative Treatment Clinic for Gliomas (CURE) in Tiantan Hospital, China

Professor Jiang Tao's Team from Beijing Tiantan Hospital Neurosurgery Leads the Establishment of China's First Advanced Innovative Treatment Clinic for Gliomas CureBreaking Through Treatment Dilemmas ...

Review and Prospect of Brain Glioma Treatment in China

Brain GliomaBrain glioma is one of the most common malignant tumors of the central nervous system. Despite numerous challenges in the treatment field, scientific advancements recently have brought new...

4th Generation CAR T Cell Therapy with IL-15: A new era in cancer treatment

Introduction Chimeric Antigen Receptor (CAR) T-cell therapy has already transformed the landscape of cancer treatment. Now, the 4th generation CAR T-cell therapy, augmented with interleukin-15 (IL-15...

Enhancing Cancer Outcomes: The Critical Role of Early CAR T-Cell Therapy

Cancer remains one of the most challenging diseases to treat, requiring innovative and effective therapies. One of the most promising advancements in cancer treatment is Chimeric Antigen Receptor (CA...

Obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia

On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...

Latest therapies in the treatment of hematological malignancies

 IntroductionHematological malignancies, such as leukemias, lymphomas, and multiple myeloma, are a heterogeneous group of cancers that arise in the bone marrow and lymphatic system. Conventional trea...

Bridging The Gaps In CAR T Cell therapy

 CAR T Cell therapyChimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary therapeutic strategy in hematologic malignancy treatment, recording high remission rates in therapy-refractory cas...

Scan the code